▶ 調査レポート

消化管間質腫瘍(GIST)治療薬の世界市場(~2026年)

• 英文タイトル:Global Gastrointestinal Stromal Tumor (GIST) Drug Market Insights and Forecast to 2026

QYResearchが調査・発行した産業分析レポートです。消化管間質腫瘍(GIST)治療薬の世界市場(~2026年) / Global Gastrointestinal Stromal Tumor (GIST) Drug Market Insights and Forecast to 2026 / MRC2-11QY06723資料のイメージです。• レポートコード:MRC2-11QY06723
• 出版社/出版日:QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、148ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医療、製薬
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User¥865,800 (USD5,850)▷ お問い合わせ
  Enterprise License¥1,154,400 (USD7,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料は消化管間質腫瘍(GIST)治療薬のグローバル市場について調査・分析したレポートです。種類別(アンカセルチブ、塩酸アナグレリドCR、APG-1351、ビニメチニブ、その他)市場規模、用途別(クリニック、病院、その他)市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別消化管間質腫瘍(GIST)治療薬の競争状況、市場シェア
・世界の消化管間質腫瘍(GIST)治療薬市場:種類別市場規模 2015年-2020年(アンカセルチブ、塩酸アナグレリドCR、APG-1351、ビニメチニブ、その他)
・世界の消化管間質腫瘍(GIST)治療薬市場:種類別市場規模予測 2021年-2026年(アンカセルチブ、塩酸アナグレリドCR、APG-1351、ビニメチニブ、その他)
・世界の消化管間質腫瘍(GIST)治療薬市場:用途別市場規模 2015年-2020年(クリニック、病院、その他)
・世界の消化管間質腫瘍(GIST)治療薬市場:用途別市場規模予測 2021年-2026年(クリニック、病院、その他)
・北米の消化管間質腫瘍(GIST)治療薬市場分析:米国、カナダ
・ヨーロッパの消化管間質腫瘍(GIST)治療薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの消化管間質腫瘍(GIST)治療薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の消化管間質腫瘍(GIST)治療薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの消化管間質腫瘍(GIST)治療薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Ariad Pharmaceuticals, Inc.、Arog Pharmaceuticals, Inc.、Array BioPharma Inc.、Astex Pharmaceuticals, Inc.、Blueprint Medicines Corporation、Boston Biomedical, Inc.、Calithera Biosciences, Inc.、Chipscreen Biosciences Ltd、Deciphera Pharmaceuticals, LLC、F. Hoffmann-La Roche Ltd.、Horizon Pharma Plc、Immunicum AB、Jiangsu Hengrui Medicine Co., Ltd.、Kolltan Pharmaceuticals, Inc.、Natco Pharma Limited、Nerviano Medical Sciences S.r.l.、Novartis AG、Omeros Corporation
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Market Analysis and Insights: Global Gastrointestinal Stromal Tumor (GIST) Drug Market
The global Gastrointestinal Stromal Tumor (GIST) Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Gastrointestinal Stromal Tumor (GIST) Drug Scope and Market Size
Gastrointestinal Stromal Tumor (GIST) Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Gastrointestinal Stromal Tumor (GIST) Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Gastrointestinal Stromal Tumor (GIST) Drug market is segmented into
Amcasertib
Anagrelide hydrochloride CR
APG-1351
Binimetinib
Others

Segment by Application, the Gastrointestinal Stromal Tumor (GIST) Drug market is segmented into
Clinic
Hospital
Others

Regional and Country-level Analysis
The Gastrointestinal Stromal Tumor (GIST) Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Gastrointestinal Stromal Tumor (GIST) Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Gastrointestinal Stromal Tumor (GIST) Drug Market Share Analysis
Gastrointestinal Stromal Tumor (GIST) Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Gastrointestinal Stromal Tumor (GIST) Drug business, the date to enter into the Gastrointestinal Stromal Tumor (GIST) Drug market, Gastrointestinal Stromal Tumor (GIST) Drug product introduction, recent developments, etc.

The major vendors covered:
Ariad Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Boston Biomedical, Inc.
Calithera Biosciences, Inc.
Chipscreen Biosciences Ltd
Deciphera Pharmaceuticals, LLC
F. Hoffmann-La Roche Ltd.
Horizon Pharma Plc
Immunicum AB
Jiangsu Hengrui Medicine Co., Ltd.
Kolltan Pharmaceuticals, Inc.
Natco Pharma Limited
Nerviano Medical Sciences S.r.l.
Novartis AG
Omeros Corporation

レポート目次

1 Study Coverage
1.1 Gastrointestinal Stromal Tumor (GIST) Drug Product Introduction
1.2 Market Segments
1.3 Key Gastrointestinal Stromal Tumor (GIST) Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size Growth Rate by Type
1.4.2 Amcasertib
1.4.3 Anagrelide hydrochloride CR
1.4.4 APG-1351
1.4.5 Binimetinib
1.4.6 Others
1.5 Market by Application
1.5.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size, Estimates and Forecasts
2.1.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue 2015-2026
2.1.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales 2015-2026
2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Gastrointestinal Stromal Tumor (GIST) Drug Competitor Landscape by Players
3.1 Gastrointestinal Stromal Tumor (GIST) Drug Sales by Manufacturers
3.1.1 Gastrointestinal Stromal Tumor (GIST) Drug Sales by Manufacturers (2015-2020)
3.1.2 Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Manufacturers
3.2.1 Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Manufacturers (2015-2020)
3.2.2 Gastrointestinal Stromal Tumor (GIST) Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Gastrointestinal Stromal Tumor (GIST) Drug Revenue in 2019
3.2.5 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Gastrointestinal Stromal Tumor (GIST) Drug Price by Manufacturers
3.4 Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base Distribution, Product Types
3.4.1 Gastrointestinal Stromal Tumor (GIST) Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Gastrointestinal Stromal Tumor (GIST) Drug Product Type
3.4.3 Date of International Manufacturers Enter into Gastrointestinal Stromal Tumor (GIST) Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Type (2015-2020)
4.1.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2015-2020)
4.1.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Type (2015-2020)
4.1.3 Gastrointestinal Stromal Tumor (GIST) Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Type (2021-2026)
4.2.3 Gastrointestinal Stromal Tumor (GIST) Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Application (2015-2020)
5.1.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2015-2020)
5.1.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Application (2015-2020)
5.1.3 Gastrointestinal Stromal Tumor (GIST) Drug Price by Application (2015-2020)
5.2 Gastrointestinal Stromal Tumor (GIST) Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Gastrointestinal Stromal Tumor (GIST) Drug by Country
6.1.1 North America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country
6.1.2 North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Type
6.3 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Application

7 Europe
7.1 Europe Gastrointestinal Stromal Tumor (GIST) Drug by Country
7.1.1 Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country
7.1.2 Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Type
7.3 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug by Region
8.1.1 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales by Region
8.1.2 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Type
8.3 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Application

9 Latin America
9.1 Latin America Gastrointestinal Stromal Tumor (GIST) Drug by Country
9.1.1 Latin America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country
9.1.2 Latin America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Type
9.3 Central & South America Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug by Country
10.1.1 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country
10.1.2 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Type
10.3 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Application

11 Company Profiles
11.1 Ariad Pharmaceuticals, Inc.
11.1.1 Ariad Pharmaceuticals, Inc. Corporation Information
11.1.2 Ariad Pharmaceuticals, Inc. Description and Business Overview
11.1.3 Ariad Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
11.1.5 Ariad Pharmaceuticals, Inc. Related Developments
11.2 Arog Pharmaceuticals, Inc.
11.2.1 Arog Pharmaceuticals, Inc. Corporation Information
11.2.2 Arog Pharmaceuticals, Inc. Description and Business Overview
11.2.3 Arog Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
11.2.5 Arog Pharmaceuticals, Inc. Related Developments
11.3 Array BioPharma Inc.
11.3.1 Array BioPharma Inc. Corporation Information
11.3.2 Array BioPharma Inc. Description and Business Overview
11.3.3 Array BioPharma Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
11.3.5 Array BioPharma Inc. Related Developments
11.4 Astex Pharmaceuticals, Inc.
11.4.1 Astex Pharmaceuticals, Inc. Corporation Information
11.4.2 Astex Pharmaceuticals, Inc. Description and Business Overview
11.4.3 Astex Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
11.4.5 Astex Pharmaceuticals, Inc. Related Developments
11.5 Blueprint Medicines Corporation
11.5.1 Blueprint Medicines Corporation Corporation Information
11.5.2 Blueprint Medicines Corporation Description and Business Overview
11.5.3 Blueprint Medicines Corporation Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
11.5.5 Blueprint Medicines Corporation Related Developments
11.6 Boston Biomedical, Inc.
11.6.1 Boston Biomedical, Inc. Corporation Information
11.6.2 Boston Biomedical, Inc. Description and Business Overview
11.6.3 Boston Biomedical, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
11.6.5 Boston Biomedical, Inc. Related Developments
11.7 Calithera Biosciences, Inc.
11.7.1 Calithera Biosciences, Inc. Corporation Information
11.7.2 Calithera Biosciences, Inc. Description and Business Overview
11.7.3 Calithera Biosciences, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
11.7.5 Calithera Biosciences, Inc. Related Developments
11.8 Chipscreen Biosciences Ltd
11.8.1 Chipscreen Biosciences Ltd Corporation Information
11.8.2 Chipscreen Biosciences Ltd Description and Business Overview
11.8.3 Chipscreen Biosciences Ltd Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
11.8.5 Chipscreen Biosciences Ltd Related Developments
11.9 Deciphera Pharmaceuticals, LLC
11.9.1 Deciphera Pharmaceuticals, LLC Corporation Information
11.9.2 Deciphera Pharmaceuticals, LLC Description and Business Overview
11.9.3 Deciphera Pharmaceuticals, LLC Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
11.9.5 Deciphera Pharmaceuticals, LLC Related Developments
11.10 F. Hoffmann-La Roche Ltd.
11.10.1 F. Hoffmann-La Roche Ltd. Corporation Information
11.10.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
11.10.3 F. Hoffmann-La Roche Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
11.10.5 F. Hoffmann-La Roche Ltd. Related Developments
11.1 Ariad Pharmaceuticals, Inc.
11.1.1 Ariad Pharmaceuticals, Inc. Corporation Information
11.1.2 Ariad Pharmaceuticals, Inc. Description and Business Overview
11.1.3 Ariad Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
11.1.5 Ariad Pharmaceuticals, Inc. Related Developments
11.12 Immunicum AB
11.12.1 Immunicum AB Corporation Information
11.12.2 Immunicum AB Description and Business Overview
11.12.3 Immunicum AB Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Immunicum AB Products Offered
11.12.5 Immunicum AB Related Developments
11.13 Jiangsu Hengrui Medicine Co., Ltd.
11.13.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
11.13.2 Jiangsu Hengrui Medicine Co., Ltd. Description and Business Overview
11.13.3 Jiangsu Hengrui Medicine Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Jiangsu Hengrui Medicine Co., Ltd. Products Offered
11.13.5 Jiangsu Hengrui Medicine Co., Ltd. Related Developments
11.14 Kolltan Pharmaceuticals, Inc.
11.14.1 Kolltan Pharmaceuticals, Inc. Corporation Information
11.14.2 Kolltan Pharmaceuticals, Inc. Description and Business Overview
11.14.3 Kolltan Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Kolltan Pharmaceuticals, Inc. Products Offered
11.14.5 Kolltan Pharmaceuticals, Inc. Related Developments
11.15 Natco Pharma Limited
11.15.1 Natco Pharma Limited Corporation Information
11.15.2 Natco Pharma Limited Description and Business Overview
11.15.3 Natco Pharma Limited Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Natco Pharma Limited Products Offered
11.15.5 Natco Pharma Limited Related Developments
11.16 Nerviano Medical Sciences S.r.l.
11.16.1 Nerviano Medical Sciences S.r.l. Corporation Information
11.16.2 Nerviano Medical Sciences S.r.l. Description and Business Overview
11.16.3 Nerviano Medical Sciences S.r.l. Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Nerviano Medical Sciences S.r.l. Products Offered
11.16.5 Nerviano Medical Sciences S.r.l. Related Developments
11.17 Novartis AG
11.17.1 Novartis AG Corporation Information
11.17.2 Novartis AG Description and Business Overview
11.17.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.17.4 Novartis AG Products Offered
11.17.5 Novartis AG Related Developments
11.18 Omeros Corporation
11.18.1 Omeros Corporation Corporation Information
11.18.2 Omeros Corporation Description and Business Overview
11.18.3 Omeros Corporation Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Omeros Corporation Products Offered
11.18.5 Omeros Corporation Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Gastrointestinal Stromal Tumor (GIST) Drug Market Estimates and Projections by Region
12.1.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Regions 2021-2026
12.2 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Size Forecast (2021-2026)
12.2.1 North America: Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast (2021-2026)
12.2.2 North America: Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast (2021-2026)
12.2.3 North America: Gastrointestinal Stromal Tumor (GIST) Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast (2021-2026)
12.3.2 Europe: Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Gastrointestinal Stromal Tumor (GIST) Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Gastrointestinal Stromal Tumor (GIST) Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Gastrointestinal Stromal Tumor (GIST) Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Gastrointestinal Stromal Tumor (GIST) Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Gastrointestinal Stromal Tumor (GIST) Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Gastrointestinal Stromal Tumor (GIST) Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Gastrointestinal Stromal Tumor (GIST) Drug Market Segments
Table 2. Ranking of Global Top Gastrointestinal Stromal Tumor (GIST) Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Amcasertib
Table 5. Major Manufacturers of Anagrelide hydrochloride CR
Table 6. Major Manufacturers of APG-1351
Table 7. Major Manufacturers of Binimetinib
Table 8. Major Manufacturers of Others
Table 9. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Regions (2015-2020)
Table 13. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Share by Manufacturers (2015-2020)
Table 16. Global Gastrointestinal Stromal Tumor (GIST) Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Gastrointestinal Stromal Tumor (GIST) Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gastrointestinal Stromal Tumor (GIST) Drug as of 2019)
Table 18. Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Gastrointestinal Stromal Tumor (GIST) Drug Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Gastrointestinal Stromal Tumor (GIST) Drug Price (2015-2020) (USD/Pcs)
Table 21. Gastrointestinal Stromal Tumor (GIST) Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Gastrointestinal Stromal Tumor (GIST) Drug Product Type
Table 23. Date of International Manufacturers Enter into Gastrointestinal Stromal Tumor (GIST) Drug Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2015-2020) (K Pcs)
Table 26. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Share by Type (2015-2020)
Table 27. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Share by Type (2015-2020)
Table 29. Gastrointestinal Stromal Tumor (GIST) Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2015-2020) (K Pcs)
Table 31. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Share by Application (2015-2020)
Table 32. North America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2015-2020) (K Pcs)
Table 33. North America Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country (2015-2020)
Table 34. North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2015-2020)
Table 36. North America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2015-2020) (K Pcs)
Table 37. North America Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2015-2020)
Table 38. North America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2015-2020) (K Pcs)
Table 39. North America Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2015-2020)
Table 40. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country (2015-2020)
Table 42. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2015-2020)
Table 44. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2015-2020)
Table 46. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2015-2020)
Table 56. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2015-2020)
Table 60. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2015-2020)
Table 62. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2015-2020)
Table 72. Ariad Pharmaceuticals, Inc. Corporation Information
Table 73. Ariad Pharmaceuticals, Inc. Description and Major Businesses
Table 74. Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Ariad Pharmaceuticals, Inc. Product
Table 76. Ariad Pharmaceuticals, Inc. Recent Development
Table 77. Arog Pharmaceuticals, Inc. Corporation Information
Table 78. Arog Pharmaceuticals, Inc. Description and Major Businesses
Table 79. Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Arog Pharmaceuticals, Inc. Product
Table 81. Arog Pharmaceuticals, Inc. Recent Development
Table 82. Array BioPharma Inc. Corporation Information
Table 83. Array BioPharma Inc. Description and Major Businesses
Table 84. Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Array BioPharma Inc. Product
Table 86. Array BioPharma Inc. Recent Development
Table 87. Astex Pharmaceuticals, Inc. Corporation Information
Table 88. Astex Pharmaceuticals, Inc. Description and Major Businesses
Table 89. Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Astex Pharmaceuticals, Inc. Product
Table 91. Astex Pharmaceuticals, Inc. Recent Development
Table 92. Blueprint Medicines Corporation Corporation Information
Table 93. Blueprint Medicines Corporation Description and Major Businesses
Table 94. Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Blueprint Medicines Corporation Product
Table 96. Blueprint Medicines Corporation Recent Development
Table 97. Boston Biomedical, Inc. Corporation Information
Table 98. Boston Biomedical, Inc. Description and Major Businesses
Table 99. Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. Boston Biomedical, Inc. Product
Table 101. Boston Biomedical, Inc. Recent Development
Table 102. Calithera Biosciences, Inc. Corporation Information
Table 103. Calithera Biosciences, Inc. Description and Major Businesses
Table 104. Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 105. Calithera Biosciences, Inc. Product
Table 106. Calithera Biosciences, Inc. Recent Development
Table 107. Chipscreen Biosciences Ltd Corporation Information
Table 108. Chipscreen Biosciences Ltd Description and Major Businesses
Table 109. Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 110. Chipscreen Biosciences Ltd Product
Table 111. Chipscreen Biosciences Ltd Recent Development
Table 112. Deciphera Pharmaceuticals, LLC Corporation Information
Table 113. Deciphera Pharmaceuticals, LLC Description and Major Businesses
Table 114. Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 115. Deciphera Pharmaceuticals, LLC Product
Table 116. Deciphera Pharmaceuticals, LLC Recent Development
Table 117. F. Hoffmann-La Roche Ltd. Corporation Information
Table 118. F. Hoffmann-La Roche Ltd. Description and Major Businesses
Table 119. F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 120. F. Hoffmann-La Roche Ltd. Product
Table 121. F. Hoffmann-La Roche Ltd. Recent Development
Table 122. Horizon Pharma Plc Corporation Information
Table 123. Horizon Pharma Plc Description and Major Businesses
Table 124. Horizon Pharma Plc Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 125. Horizon Pharma Plc Product
Table 126. Horizon Pharma Plc Recent Development
Table 127. Immunicum AB Corporation Information
Table 128. Immunicum AB Description and Major Businesses
Table 129. Immunicum AB Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 130. Immunicum AB Product
Table 131. Immunicum AB Recent Development
Table 132. Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
Table 133. Jiangsu Hengrui Medicine Co., Ltd. Description and Major Businesses
Table 134. Jiangsu Hengrui Medicine Co., Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 135. Jiangsu Hengrui Medicine Co., Ltd. Product
Table 136. Jiangsu Hengrui Medicine Co., Ltd. Recent Development
Table 137. Kolltan Pharmaceuticals, Inc. Corporation Information
Table 138. Kolltan Pharmaceuticals, Inc. Description and Major Businesses
Table 139. Kolltan Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 140. Kolltan Pharmaceuticals, Inc. Product
Table 141. Kolltan Pharmaceuticals, Inc. Recent Development
Table 142. Natco Pharma Limited Corporation Information
Table 143. Natco Pharma Limited Description and Major Businesses
Table 144. Natco Pharma Limited Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 145. Natco Pharma Limited Product
Table 146. Natco Pharma Limited Recent Development
Table 147. Nerviano Medical Sciences S.r.l. Corporation Information
Table 148. Nerviano Medical Sciences S.r.l. Description and Major Businesses
Table 149. Nerviano Medical Sciences S.r.l. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 150. Nerviano Medical Sciences S.r.l. Product
Table 151. Nerviano Medical Sciences S.r.l. Recent Development
Table 152. Novartis AG Corporation Information
Table 153. Novartis AG Description and Major Businesses
Table 154. Novartis AG Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 155. Novartis AG Product
Table 156. Novartis AG Recent Development
Table 157. Omeros Corporation Corporation Information
Table 158. Omeros Corporation Description and Major Businesses
Table 159. Omeros Corporation Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 160. Omeros Corporation Product
Table 161. Omeros Corporation Recent Development
Table 162. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 163. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share Forecast by Regions (2021-2026)
Table 164. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 165. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 166. North America: Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 167. North America: Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 168. Europe: Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 169. Europe: Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 170. Asia Pacific: Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 171. Asia Pacific: Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 172. Latin America: Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 173. Latin America: Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 174. Middle East and Africa: Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 175. Middle East and Africa: Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 176. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 177. Key Challenges
Table 178. Market Risks
Table 179. Main Points Interviewed from Key Gastrointestinal Stromal Tumor (GIST) Drug Players
Table 180. Gastrointestinal Stromal Tumor (GIST) Drug Customers List
Table 181. Gastrointestinal Stromal Tumor (GIST) Drug Distributors List
Table 182. Research Programs/Design for This Report
Table 183. Key Data Information from Secondary Sources
Table 184. Key Data Information from Primary Sources
List of Figures
Figure 1. Gastrointestinal Stromal Tumor (GIST) Drug Product Picture
Figure 2. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Amcasertib Product Picture
Figure 4. Anagrelide hydrochloride CR Product Picture
Figure 5. APG-1351 Product Picture
Figure 6. Binimetinib Product Picture
Figure 7. Others Product Picture
Figure 8. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application in 2020 & 2026
Figure 9. Clinic
Figure 10. Hospital
Figure 11. Others
Figure 12. Gastrointestinal Stromal Tumor (GIST) Drug Report Years Considered
Figure 13. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size 2015-2026 (US$ Million)
Figure 14. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales 2015-2026 (K Pcs)
Figure 15. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Region (2015-2020)
Figure 17. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Region in 2019
Figure 18. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Region (2015-2020)
Figure 19. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Region in 2019
Figure 20. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Gastrointestinal Stromal Tumor (GIST) Drug Revenue in 2019
Figure 22. Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2015-2020)
Figure 24. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type in 2019
Figure 25. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Type (2015-2020)
Figure 26. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Type in 2019
Figure 27. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Price Range (2015-2020)
Figure 28. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2015-2020)
Figure 29. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application in 2019
Figure 30. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Application (2015-2020)
Figure 31. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Application in 2019
Figure 32. North America Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country in 2019
Figure 35. North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country in 2019
Figure 36. U.S. Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Type in 2019
Figure 41. North America Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Application in 2019
Figure 42. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country in 2019
Figure 45. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country in 2019
Figure 46. Germany Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Type in 2019
Figure 57. Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Application in 2019
Figure 58. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Region in 2019
Figure 61. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Region in 2019
Figure 62. China Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Type in 2019
Figure 85. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Application in 2019
Figure 86. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country in 2019
Figure 89. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country in 2019
Figure 90. Mexico Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Type in 2019
Figure 97. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Application in 2019
Figure 98. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country in 2019
Figure 102. Turkey Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Type in 2019
Figure 109. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Application in 2019
Figure 110. North America Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed